🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT06870370
Starting soon Phase 3

Role of Non-Selective Beta-Adrenergic Blocker in Severe TBI

NCT06870370 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 3
Started
2025-09-20
Last updated
2025-03-11

Condition(s) studied

Traumatic Brain Injury (TBI) PatientsIntracranial PressureIntensive Care UnitMortality

Investigational drug(s) / intervention(s)

propranolol →normal saline IV

propranolol: This group Will receive propranolol intravenously at a dose of 1 mg every 6 h for 7 days, and doses will be held if heart rate less than 60 bpm, mean arterial pressure less than 65 mmHg

normal saline IV: This group Will receive 1ml of sterile 0.9% normal saline IV every 6 hours for 7 days

Study summary

The role of nonselective beta adrenergic blocker as antistress agent in severe traumatic brain injury

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged between 18and 65 years old * Patients who have Severe traumatic brain injury * Glascow outcome scale ≤ 8 Exclusion Criteria: * Patients have pre-existing heart disease. * If there are contraindications to β blocker. * penetrating traumatic brain injury. * pre-injury brain dysfunction. * β-blocker or α2-agonist use before trauma.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tanta University Tanta Egypt

More Tanta University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06870370 on ClinicalTrials.gov ↗ ← All trials in Egypt